The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Inflammation. Basic principles and clinical correlates
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90156-x · Cited by 2,393
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Long-Term Potentiation and Memory
LYNCH, M. A. (2004) · Physiological Reviews · doi:10.1152/physrev.00014.2003 · Cited by 1,991
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Common variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677 · cited 1×
“Interestingly, schizophrenia GWAS have consistently implicated genetic variants in the major histocompatibility complex (MHC) on chromosome 6 as common susceptibility factor for the disorder (Purcell et al., 2009; Shi et al., 2009; Stefansson et al., 2009).”
BackgroundMaternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
The neuropsychology of schizophrenia
Gray, J. A., Feldon, J., Rawlins, J. N. P., Hemsley, D. R., & Smith, A. D. (1991) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00065055 · Cited by 1,350
Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,346
Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies
Brown, A. S., & Derkits, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030361 · Cited by 1,269
Raison, C. L., & Miller, A. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1554 · Cited by 1,197
Common variants on chromosome 6p22.1 are associated with schizophrenia
Shi, J., Levinson, D. F., Duan, J., Sanders, A. R., Zheng, Y., Pe’er, I., Dudbridge, F., Holmans, P. A., Whittemore, A. S., Mowry, B. J., et al. (2009) · Nature · doi:10.1038/nature08192 · Cited by 1,170
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Diagnosing schizophrenia in the initial prodromal phase
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M., & Schultze-Lutter, F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.158 · Cited by 1,049
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
Early Life Programming and Neurodevelopmental Disorders
Bale, T. L., Baram, T. Z., Brown, A. S., Goldstein, J. M., Insel, T. R., McCarthy, M. M., Nemeroff, C. B., Reyes, T. M., Simerly, R. B., Susser, E. S., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.028 · Cited by 961
IL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi, S. H., & Folsom, T. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn187 · Cited by 860
Hilmas, C., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 859
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.024 · Cited by 858
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 1×
“…cognitive impairments may primarily affect domains of executive functions, sustained attention andworkingmemory (Marsland et al., 2006; Holden et al., 2008; Cohen et al., 2011), all ofwhich have been implicated in schizophrenia (Elvevåg & Goldberg, 2000; Bowie & Harvey, 2006; Tandon et al., 2009).”
BackgroundFunctional requirement for class I MHC in CNS development and plasticity
Huh, G. S., Boulanger, L. M., Du, H., Riquelme, P. A., Brotz, T. M., & Shatz, C. J. (2000) · Science · doi:10.1126/science.290.5499.2155 · Cited by 828
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791
Evidence for a cytokine model of cognitive function
McAfoose, J., & Baune, B. T. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.10.005 · Cited by 760
Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology
TANDON, R., KESHAVAN, M., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.011 · Cited by 720
Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence
Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.237 · Cited by 688
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Self-citationEarly-life programming of later-life brain and behavior: a critical role for the immune system
Bilbo, S. D. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.014.2009 · Cited by 652 · cited 3×
“In this scenario, immunological exposure in early (prenatal or neonatal) life can cause the organism to mount exacerbated reactions to subsequent immunological or non-immunological challenges in later life (Bilbo & Schwarz, 2009; Meyer et al., 2011).”
BackgroundInflammation: Basic Principles and Clinical Correlates
Ehrlich, G. E. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.1.123 · Cited by 622
Preclinical and clinical research on inflammation after intracerebral hemorrhage
Wang, J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.08.001 · Cited by 602
The Left Striato-pallidal Hyperactivity Model of Schizophrenia
Early, T. S., Haller, J. W., Posner, M. I., & Raichle, M. (2019) · The Neuropsychology of Schizophrenia · doi:10.4324/9781315785004-2 · Cited by 598
Social skills deficits associated with depression
Segrin, C. (2000) · Clinical Psychology Review · doi:10.1016/s0272-7358(98)00104-4 · Cited by 590
van Berckel, B. N., Bossong, M. G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A. D., Cahn, W., Lammertsma, A. A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.025 · Cited by 582
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R. A., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 559
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556
Immune proteins in brain development and synaptic plasticity
Boulanger, L. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.001 · Cited by 555
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
Cytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508
The Initial Prodrome in Psychosis: Descriptive and Qualitative Aspects
Yung, A. R., & McGorry, P. D. (1996) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679609062654 · Cited by 506
A neuromodulatory role of interleukin-1β in the hippocampus
Schneider, H., Pitossi, F., Balschun, D., Wagner, A., del Rey, A., & Besedovsky, H. O. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7778 · Cited by 498
Wyatt, R. J., Alexander, R. C., Egan, M. F., & Kirch, D. G. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90034-5 · Cited by 477
Biology of the Interleukin-2 Receptor
Nelson, B. H., & Willerford, D. M. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60386-7 · Cited by 475
Oxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 472
Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship?
Harvey, P. D., Koren, D., Reichenberg, A., & Bowie, C. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj011 · Cited by 462
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6
Zalcman, S., Green-Johnson, J. M., Murray, L., Nance, D. M., Dyck, D., Anisman, H., & Greenberg, A. H. (1994) · Brain Research · doi:10.1016/0006-8993(94)90006-x · Cited by 439
Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response
MURRAY, P. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.010 · Cited by 436
The neuropoietic cytokine family in development, plasticity, disease and injury
Bauer, S., Kerr, B. J., & Patterson, P. H. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2054 · Cited by 419
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Cellular and molecular basis for the regulation of inflammation by TGF-
Yoshimura, A., Wakabayashi, Y., & Mori, T. (2010) · Journal of Biochemistry · doi:10.1093/jb/mvq043 · Cited by 391
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationLevkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Redox dysregulation, neurodevelopment, and schizophrenia
Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384
Brydon, L., Harrison, N. A., Walker, C., Steptoe, A., & Critchley, H. D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.12.007 · Cited by 381 · cited 2×
“, 2008) and psychomotor retardation (Brydon et al., 2008).”
BackgroundEpidemiology-driven neurodevelopmental animal models of schizophrenia
Meyer, U., & Feldon, J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.018 · Cited by 372
Self-citationMHC Class I: An Unexpected Role in Neuronal Plasticity
Shatz, C. J. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.044 · Cited by 372
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364
Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation?
MEYER, U., FELDON, J., & DAMMANN, O. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e318212c196 · Cited by 357 · cited 5×
“…and cellularmechanisms remain to be identified, it has been suggested that enhanced pro-inflammatory activity in general, andmicroglia over-activation in particular, may play a role in precipitating such progressive brain changes in schizophrenia (van Berckel et al., 2008; Meyer et al., 2011).”
BackgroundInfluentialSelf-citationSanders, A. R., Duan, J., Levinson, D. F., Shi, J., He, D., Hou, C., Burrell, G. J., Rice, J. P., Nertney, D. A., Olincy, A., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07101573 · Cited by 349
Increase in HLA-DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics
Radewicz, K., Garey, L. J., Gentleman, S. M., & Reynolds, R. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.2.137 · Cited by 342
Effects of cytokines and infections on brain neurochemistry
Dunn, A. J. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.04.002 · Cited by 336
Immune signalling in neural development, synaptic plasticity and disease
Boulanger, L. M., & Shatz, C. J. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1428 · Cited by 334
Haack, M., Hinze-Selch, D., Fenzel, T., Kraus, T., Kühn, M., Schuld, A., & Pollmächer, T. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00021-7 · Cited by 329
Arion, D., Unger, T., Lewis, D. A., Levitt, P., & Mirnics, K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.021 · Cited by 329
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M.-L., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq086 · Cited by 325
Evidence for activation of microglia in patients with psychiatric illnesses
Bayer, T. A., Buslei, R., Havas, L., & Falkai, P. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00545-5 · Cited by 323
Sullivan, P. F. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020212 · Cited by 321
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6
Lin, A., Kenis, G., Bignotti, S., Tura, G.-J.-B., De Jong, R., Bosmans, E., Pioli, R., Altamura, C., Scharpé, S., & Maes, M. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00034-6 · Cited by 321
A Review of the Fetal Brain Cytokine Imbalance Hypothesis of Schizophrenia
Meyer, U., Feldon, J., & Yee, B. K. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn022 · Cited by 320
Self-citationA primer on cytokines: sources, receptors, effects, and inducers
Curfs, J. H., Meis, J. F., & Hoogkamp-Korstanje, J. A. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.4.742 · Cited by 317
Interleukin‐6: a cytokine to forget
Balschun, D., Wetzel, W., del Rey, A., Pitossi, F., Schneider, H., Zuschratter, W., & Besedovsky, H. O. (2004) · The FASEB Journal · doi:10.1096/fj.04-1625fje · Cited by 317
Borrell, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00360-8 · Cited by 307
Behavioral Effects of Cytokines
Larson, S. J., & Dunn, A. J. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2001.0643 · Cited by 296
The Role of Immune System in Schizophrenia
Muller, N., & J. Schwarz, M. (2010) · Current Immunology Reviews · doi:10.2174/157339510791823673 · Cited by 291
AKHONDZADEH, S., TABATABAEE, M., AMINI, H., AHMADIABHARI, S., ABBASI, S., & BEHNAM, B. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.016 · Cited by 289
Samuelsson, A.-M., Jennische, E., Hansson, H.-A., & Holmäng, A. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00268.2005 · Cited by 285
Stress as a neuroinflammatory condition in brain: Damaging and protective mechanisms
García-Bueno, B., Caso, J. R., & Leza, J. C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.04.001 · Cited by 280
Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers
Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L., & Curran, H. V. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300342 · Cited by 277
A naturalistic visual scanning approach to assess selective attention in major depressive disorder
Eizenman, M., Yu, L. H., Grupp, L., Eizenman, E., Ellenbogen, M., Gemar, M., & Levitan, R. D. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00068-4 · Cited by 272
Laan, W., Grobbee, D. E., Selten, J.-P., Heijnen, C. J., Kahn, R. S., & Burger, H. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05117yel · Cited by 264
Drexhage, R. C., Knijff, E. M., Padmos, R. C., Heul-Nieuwenhuijzen, L. V. D., Beumer, W., Versnel, M. A., & Drexhage, H. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.144 · Cited by 263
Prenatal stress, fetal imprinting and immunity
Merlot, E., Couret, D., & Otten, W. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.05.007 · Cited by 259
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Meyer, U., Murray, P. J., Urwyler, A., Yee, B. K., Schedlowski, M., & Feldon, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002042 · Cited by 252
Self-citationMüller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Möller, H.-J., Klauss, V., Schwarz, M. J., & Riedel, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.015 · Cited by 250
Self-citationGenomic Organization of the Mammalian Mhc
Kumánovics, A., Takada, T., & Lindahl, K. F. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.090501.080116 · Cited by 247
Cytokines in schizophrenia and the effects of antipsychotic drugs
Drzyzga, Ł., Obuchowicz, E., Marcinowska, A., & Herman, Z. S. (2006) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.02.002 · Cited by 242
Bianchi, R., Kastrisianaki, E., Giambanco, I., & Donato, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.169342 · Cited by 239
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia
Nilsson, L. K., Linderholm, K. R., Engberg, G., Paulson, L., Blennow, K., Lindström, L. H., Nordin, C., Karanti, A., Persson, P., & Erhardt, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.013 · Cited by 238
Immune‐inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine
Maes, M., Meltzer, H. Y., & Bosmans, E. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01527.x · Cited by 237
Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization
Steiner, J., Mawrin, C., Ziegeler, A., Bielau, H., Ullrich, O., Bernstein, H.-G., & Bogerts, B. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0090-8 · Cited by 229
Phillips, L. J., Mcgorry, P. D., Garner, B., Thompson, K. N., Pantelis, C., Wood, S. J., & Berger, G. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01877.x · Cited by 228
Elevations of Endogenous Kynurenic Acid Produce Spatial Working Memory Deficits
Chess, A. C., Simoni, M. K., Alling, T. E., & Bucci, D. J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl033 · Cited by 225
Woods, S. W., Breier, A., Zipursky, R. B., Perkins, D. O., Addington, J., Miller, T. J., Hawkins, K. A., Marquez, E., Lindborg, S. R., Tohen, M., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00321-4 · Cited by 223
Vuillermot, S., Weber, L., Feldon, J., & Meyer, U. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5408-09.2010 · Cited by 217
Self-citationMcGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T. J., Woods, S. W., Hawkins, K. A., Hoffman, R., Lindborg, S., Tohen, M., et al. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00439-5 · Cited by 215
Genetics of psychosis; insights from views across the genome
O’Donovan, M. C., Craddock, N. J., & Owen, M. J. (2009) · Human Genetics · doi:10.1007/s00439-009-0703-0 · Cited by 215
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
The role of serotonin in the pathophysiology and treatment of schizophrenia
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.1.1 · Cited by 211
Early Detection and Intervention in Schizophrenia: Research
McGlashan, T. H. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.327 · Cited by 210
Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia
GILMORE, J., & FREDRIKJARSKOG, L. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00123-5 · Cited by 209
Zhang, X. Y., Zhou, D. F., Cao, L. Y., Wu, G. Y., & Shen, Y. C. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300756 · Cited by 209
Dickerson, F., Stallings, C., Origoni, A., Boronow, J., & Yolken, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.022 · Cited by 205
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1291 · Cited by 204
Larson, M. K., Walker, E. F., & Compton, M. T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.93 · Cited by 203
Zhang, X. Y., Zhou, D. F., Zhang, P. Y., Wu, G. Y., Cao, L. Y., & Shen, Y. C. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00296-1 · Cited by 198
Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data
Jia, P., Wang, L., Meltzer, H. Y., & Zhao, Z. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.001 · Cited by 196
Wood, S. J., Pantelis, C., Velakoulis, D., Yucel, M., Fornito, A., & McGorry, P. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm149 · Cited by 195
Sugino, H., Futamura, T., Mitsumoto, Y., Maeda, K., & Marunaka, Y. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.006 · Cited by 191
Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia
Wonodi, I., & Schwarcz, R. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190
Kunz, M., Ceresér, K. M., Goi, P. D., Fries, G. R., Teixeira, A. L., Fernandes, B. S., Belmonte-de-Abreu, P. S., Kauer-Sant'Anna, M., Kapczinski, F., & Gama, C. S. (2011) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462011000300010 · Cited by 190
The Immune System and Schizophrenia: An Integrative View
MÜLLER, N., RIEDEL, M., GRUBER, R., ACKENHEIL, M., & SCHWARZ, M. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05410.x · Cited by 189
Self-citationGlial cells in schizophrenia: pathophysiological significance and possible consequences for therapy
Bernstein, H.-G., Steiner, J., & Bogerts, B. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.59 · Cited by 189
Theodoropoulou, S., Spanakos, G., Baxevanis, C. N., Economou, M., Gritzapis, A. D., Papamichail, M. P., & Stefanis, C. N. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00007-4 · Cited by 187
Th1, Th2 and Th3 cytokine alteration in schizophrenia
Kim, Y.-K., Myint, A.-M., Lee, B.-H., Han, C.-S., Lee, H.-J., Kim, D.-J., & Leonard, B. E. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.047 · Cited by 187
The Interaction of Nuclear Factor-Kappa B and Cytokines Is Associated with Schizophrenia
Song, X.-Q., Lv, L.-X., Li, W.-Q., Hao, Y.-H., & Zhao, J.-P. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.018 · Cited by 187
Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1408 · Cited by 185
Effects of antipsychotic drugs on cytokine networks
Pollmächer, T., Haack, M., Schuld, A., Kraus, T., & Hinze-Selch, D. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00032-7 · Cited by 181
Association between −G308A tumor necrosis factor alpha gene polymorphism and schizophrenia
Boin, F., Zanardini, R., Pioli, R., Altamura, C. A., Maes, M., & Gennarelli, M. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000815 · Cited by 179
Activation of brain interleukin-1β in schizophrenia
Söderlund, J., Schröder, J., Nordin, C., Samuelsson, M., Walther-Jallow, L., Karlsson, H., Erhardt, S., & Engberg, G. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.52 · Cited by 179
Interleukin-6 Covaries Inversely With Cognitive Performance Among Middle-Aged Community Volunteers
Marsland, A. L., Petersen, K. L., Sathanoori, R., Muldoon, M. F., Neumann, S. A., Ryan, C., Flory, J. D., & Manuck, S. B. (2006) · Psychosomatic Medicine · doi:10.1097/01.psy.0000238451.22174.92 · Cited by 179
In vivo immunomodulatory effects of clozapine in schizophrenia
Maes, M., Bosmans, E., Kenis, G., De Jong, R., Smith, R. S., & Meltzer, H. Y. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00057-1 · Cited by 178
Whitaker, L. C. (1992) · Schizophrenic Disorders · doi:10.1007/978-1-4757-2159-1_10 · Cited by 174
When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits
Garey, L. J. (2010) · Journal of Anatomy · doi:10.1111/j.1469-7580.2010.01231.x · Cited by 174
Hope, S., Melle, I. S., Aukrust, P., Steen, N. E., Birkenaes, A. B., Lorentzen, S., Agartz, I., Ueland, T., & Andreassen, O. A. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00757.x · Cited by 171
Neuronal plasticity and cellular immunity: shared molecular mechanisms
Boulanger, L. M., Huh, G. S., & Shatz, C. J. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00251-8 · Cited by 171
Drexhage, R. C., Hoogenboezem, T. A., Cohen, D., Versnel, M. A., Nolen, W. A., van Beveren, N. J. M., & Drexhage, H. A. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001653 · Cited by 169
Proposal for a noradrenaline hypothesis of schizophrenia
Yamamoto, K.-I., & Hornykiewicz, O. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.033 · Cited by 166
Romero, E., Guaza, C., Castellano, B., & Borrell, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.44 · Cited by 163
Meyer, U., Engler, A., Weber, L., Schedlowski, M., & Feldon, J. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.031 · Cited by 160
Self-citationMcGlashan, T. H. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.5.790 · Cited by 160
Fan, X., Pristach, C., Liu, E. Y., Freudenreich, O., Henderson, D. C., & Goff, D. C. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.07.011 · Cited by 159
Kim, Y.-K., Kim, L., & Lee, M.-S. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00171-1 · Cited by 158
Elevated Interleukin-6 in the Cerebrospinal Fluid of a Previously Delineated Schizophrenia Subtype
Garver, D. L., Tamas, R. L., & Holcomb, J. A. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300217 · Cited by 148
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
Song, C., Lin, A., Kenis, G., Bosmans, E., & Maes, M. H. J. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00116-4 · Cited by 144
A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia?
Naudin, J., Capo, C., Giusano, B., Mège, J. L., & Azorin, J. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00059-5 · Cited by 141
Curran, B. P., & O'Connor, J. J. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00405-5 · Cited by 138
Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia
Rapaport, M. H., Delrahim, K. K., Bresee, C. J., Maddux, R. E., Ahmadpour, O. A., & Dolnak, D. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.024 · Cited by 137
Kim, Y., Myint, A.-M., Verkerk, R. M., Scharpé, S., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Neuropsychobiology · doi:10.1159/000213565 · Cited by 135
Clinical effects of COX?2 inhibitors on cognition in schizophrenia
M�ller, N., Riedel, M. J., Schwarz, M., & Engel, R. R. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0548-4 · Cited by 135
Self-citationGardoni, F., Boraso, M., Zianni, E., Corsini, E., Galli, C. L., Cattabeni, F., Marinovich, M., Luca, M. D., & Viviani, B. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-14 · Cited by 131
Yang, C. R., & Svensson, K. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.004 · Cited by 130
Cellular immunity in schizophrenic patients before and during neuroleptic treatment
Müller, N., Ackenheil, M., Hofschuster, E., Mempel, W., & Eckstein, R. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90072-w · Cited by 130
Self-citationInflammation and schizophrenia
Fan, X., GOFF, D. C., & Henderson, D. C. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.789 · Cited by 130
Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls
Reale, M., Patruno, A., Lutiis, M. A. D., Pesce, M., Felaco, M., Giannantonio, M. D., Nicola, M. D., & Grilli, A. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-13 · Cited by 128
Müller, N., Empl, M., Riedel, M. J., Schwarz, M., & Ackenheil, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02922260 · Cited by 127
Self-citationPolymorphisms of the interleukin-1 gene complex in schizophrenia
Katila, H., Hänninen, K., & Hurme, M. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000483 · Cited by 123
Maes, M. H. J., Bosmans, E., Ranjan, R., Vandoolaeghe, E., Meltzer, H. Y., LEY, M. D., Berghmans, R., Stans, G., & Desnyder, R. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(96)00029-1 · Cited by 120
Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes
Anisman, H., Kokkinidis, L., & Merali, Z. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00011-9 · Cited by 119
S100B Serum Levels and Long-Term Improvement of Negative Symptoms in Patients with Schizophrenia
Rothermundt, M., Ponath, G. D., Gläser, T., Hetzel, G., & Arolt, V. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300403 · Cited by 118
Müller, N. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00045-a · Cited by 117
Self-citationSchizophrenia susceptibility genes: emergence of positional candidates and future directions
Gogos, J. A., & Gerber, D. J. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.02.005 · Cited by 115
Akiyama, K. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00140-6 · Cited by 109
Interactions Between the Immune and Neuroendocrine Systems
Rivest, S. (2010) · Progress in brain research · doi:10.1016/s0079-6123(08)81004-7 · Cited by 108
Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., Matson, W. R., McEvoy, J. P., Kaddurah‐Daouk, R., & Yao, J. K. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001689 · Cited by 105
Immunological Dysfunction in Schizophrenia: A Systematic Approach
Rothermundt, M., Arolt, V., Weitzsch, C., Eckhoff, D., & Kirchner, H. (1998) · Neuropsychobiology · doi:10.1159/000026501 · Cited by 104
Barak, V., Barak, Y., Levine, J., Nisman, B., & Roisman, I. (1995) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.1995.6.1.61 · Cited by 103
Müller, N., Myint, A.-M., & Schwarz, M. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/nmueller · Cited by 103
Self-citationCOX-2 Inhibition in Schizophrenia and Major Depression
Müller, N., & Schwarz, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480243 · Cited by 102
Self-citationAstrocyte, the star avatar: redefined
Seth, P., & Koul, N. (2008) · Journal of Biosciences · doi:10.1007/s12038-008-0060-5 · Cited by 96
Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia
Bocchio‐Chiavetto, L., Boin, F., Zanardini, R., Popoli, M., Michelato, A., Bignotti, S., Tura, G. B., & Gennarelli, M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01324-5 · Cited by 95
Clinical evaluation of negative symptoms in schizophrenia
Möller, H. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.03.010 · Cited by 93
Cytokine profiles in schizophrenic patients treated with risperidone
Cazzullo, C. L., Sacchetti, E., Galluzzo, A., Panariello, A., Adorni, A., Pegoraro, M., Bosis, S., Colombo, F., Trabattoni, D., Zagliani, A., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00221-4 · Cited by 89
Bell, M. D., & Mishara, A. L. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.09.016 · Cited by 88
Zhang, X. Y., Zhou, D. F., Qi, L. Y., Chen, S., Cao, L. Y., Chen, D. C., Xiu, M. H., Wang, F., Wu, G. Y., Lü, L., et al. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1447-6 · Cited by 86
Elevated interleukin-6 in schizophrenia
van Kammen, D. P., McAllister, C. G., Kelley, M. E., Gurklis, J. A., & Yao, J. K. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00053-0 · Cited by 85
S100B attenuates microglia activation in gliomas: Possible role of STAT3 pathway
Zhang, L., Liu, W., Alizadeh, D., Zhao, D., Farrukh, O., Lin, J., Badie, S., & Badie, B. (2010) · Glia · doi:10.1002/glia.21118 · Cited by 83
Monocytic, Th1 and Th2 Cytokine Alterations in the Pathophysiology of Schizophrenia
Na, K.-S., & Kim, Y. (2007) · Neuropsychobiology · doi:10.1159/000111535 · Cited by 83
Bacopoulos, N. G., & BHATNAGAR, R. K. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb07780.x · Cited by 82
Fan, X., Liu, E. Y., Freudenreich, O., Park, J. H., Liu, D., Wang, J., Yi, Z., GOFF, D. C., & Henderson, D. C. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1028 · Cited by 80
Chess, A. C., & Bucci, D. J. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.03.006 · Cited by 78
Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia
Bulut, M., Savas, H. A., Altindag, A., Virit, O., & Dalkilic, A. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970903144004 · Cited by 73
Günther, T., Konrad, K., Brito, S. A. D., Herpertz‐Dahlmann, B., & Vloet, T. D. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02320.x · Cited by 71
Knüpfer, H., & Preiß, R. (2007) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100113 · Cited by 71
Schmitt, A., Leonardi‐Essmann, F., Durrenberger, P. F., Parlapani, E., Schneider-Axmann, T., Spanagel, R., Arzberger, T., Kretzschmar, H. A., Herrera‐Marschitz, M., Gruber, O., et al. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.530690 · Cited by 69
Xu, M., & He, L. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1031 · Cited by 69
Paul-Samojedny, M., Kowalczyk, M., Suchanek-Raif, R., Owczarek, A. J., Fila-Daniłow, A., Szczygiel, A., & Kowalski, J. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9365-6 · Cited by 67
Coelho, F. M., Reis, H. J., Nicolato, R., Romano‐Silva, M. A., Teixeira, M. M., Bauer, M. E., & Teixeira, A. L. (2008) · NeuroImmunoModulation · doi:10.1159/000148197 · Cited by 66
S100B in schizophrenia: an update.
Rothermundt, M., Ahn, J. N., & Jörgens, S. (2009) · PubMed · Cited by 65
Silver, H. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.10.2053 · Cited by 65
Hayley, S. P., Wall, P. M., & Anisman, H. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01936.x · Cited by 64
Cited by
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
Self-citationFelger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung, M. Y., Hu, X., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.168 · Cited by 620
Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders: A Nationwide Study
Benros, M. E., Waltoft, B. L., Nordentoft, M., Østergaard, S. D., Eaton, W. W., Krogh, J., & Mortensen, P. B. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1111 · Cited by 572
The role of inflammation in schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00372 · Cited by 465
Self-citationMolecular and functional neuroscience in immunity
Pavlov, V. A., Chavan, S. S., & Tracey, K. J. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053158 · Cited by 444
Metadata
- Authors
- Meyer, U., Schwarz, M. J., & Müller, N.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 132
- Issue
- 1
- Pages
- 96-110
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2139161910
- Cited by
- 258
- References
- 239
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.